[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: Anti-cancer drug combats MS Researchers have identified that a type of cancer drug can help people with early multiple sclerosis relapsed on previous drugs as well as patients who failed in treatment. A new study conducted at the University of Cambridge indicated that a drug which reboots a person's immune system proved to be an effective treatment for multiple sclerosis (MS) patients. According to the study published in the journal The Lancet, the drug known as ‘alemtuzumab’, which previously used to treat a type of leukemia, through wiping out and resetting the immune system, has shown better results than other current options for MS patients. The drug significantly lowers the number of attacks (or relapses) experienced by people with MS compared to those patients who are treated with current drug, interferon beta-1a. Moreover, the study revealed that patients taking alemtuzumab had less disability than when they started the trial whereas those who were on interferon therapy had experienced worsening disability. The effective result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity whilst taking an existing treatment for MS. "Although other MS drugs have emerged over the last year, which is certainly good news for patients, none has shown superior effects on disability when compared to interferon except alemtuzumab," said Dr Alasdair Coles, from the University of Cambridge. "It is certainly the most effective MS drug, based on these clinical trials, but this is definitely not a cure," he noted. MS is an autoimmune disease in which the body's immune system mistakenly attacks nerve fibres and their protective insulation. The resulting damage prevents the nerves from 'firing' properly and ultimately leads to the loss of the nerve fibre and consequently physical and cognitive disabilities. FGP/FGP LYNNE HEAL Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash. In post-marketing reports, the following serious infusion-related events were reported: syncope, pulmonary infiltrates, ARDS, respiratory arrest, cardiac arrhythmias, myocardial infarction and cardiac arrest. The cardiac adverse events have resulted in death in some cases. This DRUG is VERY dangerous AND BEING PROMOTED LYNNE HEAL Please do the research on this drug its VERY DANGEROUS on and has killed Post Comment Private Reply Ignore Thread Top • Page Up • Full Thread • Page Down • Bottom/Latest
#1. To: Tatarewicz (#0)
Great!
“The most dangerous man to any government is the man who is able to think things out... without regard to the prevailing superstitions and taboos. Almost inevitably he comes to the conclusion that the government he lives under is dishonest, insane, intolerable.” ~ H. L. Mencken |
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||